Research programme: rheumatoid arthritis therapies - Provid Pharmaceuticals
Latest Information Update: 04 Apr 2008
At a glance
- Originator Provid Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Aug 2005 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)